Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | -0.90% | |
| Oversold Stochastic | Weakness | -0.90% | |
| Oversold Stochastic | Weakness | -4.21% | |
| Stochastic Buy Signal | Bullish | -8.33% | |
| NR7 | Range Contraction | -8.33% | |
| Narrow Range Bar | Range Contraction | -8.33% | |
| Oversold Stochastic | Weakness | -8.33% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 16 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.06 |
| 52 Week Low | 6.3 |
| Average Volume | 402,495 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 8.03 |
| 20-Day Moving Average | 7.52 |
| 10-Day Moving Average | 7.08 |
| Average True Range | 0.58 |
| RSI (14) | 36.71 |
| ADX | 17.58 |
| +DI | 12.92 |
| -DI | 22.97 |
| Chandelier Exit (Long, 3 ATRs) | 7.05 |
| Chandelier Exit (Short, 3 ATRs) | 8.22 |
| Upper Bollinger Bands | 8.59 |
| Lower Bollinger Band | 6.44 |
| Percent B (%b) | 0.07 |
| BandWidth | 28.57 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.26 |
| MACD Histogram | -0.0584 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.15 | ||||
| Resistance 3 (R3) | 7.18 | 7.02 | 7.06 | ||
| Resistance 2 (R2) | 7.02 | 6.88 | 7.01 | 7.03 | |
| Resistance 1 (R1) | 6.81 | 6.80 | 6.74 | 6.78 | 7.00 |
| Pivot Point | 6.66 | 6.66 | 6.62 | 6.64 | 6.66 |
| Support 1 (S1) | 6.45 | 6.52 | 6.37 | 6.42 | 6.20 |
| Support 2 (S2) | 6.29 | 6.43 | 6.28 | 6.17 | |
| Support 3 (S3) | 6.08 | 6.29 | 6.14 | ||
| Support 4 (S4) | 6.05 |
